share_log

Intelligent Bio Solutions (NASDAQ:INBS) and Insulet (NASDAQ:PODD) Critical Review

Intelligent Bio Solutions (NASDAQ:INBS) and Insulet (NASDAQ:PODD) Critical Review

智能生物解決方案(NASDAQ:INBS)和胰島素(NASDAQ:POD)批判審查
Defense World ·  2023/01/29 01:21

Insulet (NASDAQ:PODD – Get Rating) and Intelligent Bio Solutions (NASDAQ:INBS – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

英蘇萊特(納斯達克:Podd-Get Rating)和智能生物解決方案(納斯達克:INBS-GET Rating)都是醫療公司,但哪一家業務更好?我們將根據這兩家公司的股息、收益、盈利能力、估值、分析師建議、機構所有權和風險等方面的實力進行比較。

Earnings and Valuation

收益和估值

This table compares Insulet and Intelligent Bio Solutions' gross revenue, earnings per share and valuation.

此表比較了Insulet和Intelligence Bio Solutions的毛收入、每股收益和估值。

Get
到達
Insulet
Insulet
alerts:
警報:
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Insulet $1.10 billion 18.05 $16.80 million $0.24 1,189.58
Intelligent Bio Solutions $440,000.00 34.16 -$8.31 million ($0.56) -1.46
總收入 價格/銷售額比 淨收入 每股收益 市盈率
Insulet 11.億美元 18.05 1680萬美元 $0.24 1,189.58
智能生物解決方案 $440,000.00 34.16 -831萬元 ($0.56) -1.46

Insulet has higher revenue and earnings than Intelligent Bio Solutions. Intelligent Bio Solutions is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Insulet的收入和收益高於智能生物解決方案。智能生物解決方案的市盈率低於Insulet,表明它目前是兩隻股票中更負擔得起的一隻。

Risk & Volatility

風險與波動性

Insulet has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.
Insulet的貝塔係數為0.79,這意味着其股價的波動性比標準普爾500指數低21%。相比之下,智能生物解決方案的貝塔係數為1.47,這意味着其股價的波動性比標準普爾500指數高47%。

Analyst Recommendations

分析師建議

This is a summary of recent ratings and recommmendations for Insulet and Intelligent Bio Solutions, as reported by MarketBeat.

這是MarketBeat報道的Insulet和智能生物解決方案最近的評級和推薦摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet 0 5 9 0 2.64
Intelligent Bio Solutions 0 0 0 0 N/A
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
Insulet 0 5 9 0 2.64
智能生物解決方案 0 0 0 0 不適用

Insulet currently has a consensus target price of $309.23, suggesting a potential upside of 8.31%. Given Insulet's higher possible upside, equities research analysts plainly believe Insulet is more favorable than Intelligent Bio Solutions.

Insulet目前的普遍目標價為309.23美元,暗示潛在上漲8.31%。考慮到Insulet更有可能的上行空間,股票研究分析師顯然認為Insulet比智能生物解決方案更有利。

Institutional & Insider Ownership

機構與內部人持股

2.3% of Intelligent Bio Solutions shares are owned by institutional investors. 0.9% of Insulet shares are owned by insiders. Comparatively, 1.9% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

智能生物解決方案2.3%的股份由機構投資者持有。Insulet 0.9%的股份由內部人士持有。相比之下,智能生物解決方案1.9%的股份由內部人士持有。強大的機構持股表明,對衝基金、捐贈基金和大型基金管理公司相信,一家公司的長期表現將好於大盤。

Profitability

盈利能力

This table compares Insulet and Intelligent Bio Solutions' net margins, return on equity and return on assets.

此表比較了Insulet和Intelligence Bio Solutions的淨利潤率、股本回報率和資產回報率。

Net Margins Return on Equity Return on Assets
Insulet 1.35% 18.19% 4.02%
Intelligent Bio Solutions -1,078.91% -106.09% -62.08%
淨利潤率 股本回報率 資產回報率
Insulet 1.35% 18.19% 4.02%
智能生物解決方案 -1,078.91% -106.09% -62.08%

Summary

摘要

Insulet beats Intelligent Bio Solutions on 9 of the 13 factors compared between the two stocks.

Insulet在兩隻股票比較的13個因素中有9個擊敗了智能生物解決方案。

About Insulet

關於Insulet

(Get Rating)

(獲取評級)

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Insulet Corp.是一家醫療設備公司,從事胰島素依賴型糖尿病患者胰島素輸注系統的開發、製造和營銷。它專門生產糖尿病用品,包括OmniPod系統,以及其他與糖尿病相關的產品和用品,如血糖檢測用品、傳統胰島素泵、泵用品和藥品。該公司由約翰·L·布魯克斯三世和約翰·T·加里博託於2000年7月創立,總部設在馬薩諸塞州阿克頓。

About Intelligent Bio Solutions

關於智能生物解決方案

(Get Rating)

(獲取評級)

Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

智能生物解決方案公司是一家生命科學公司,為患者及其初級健康從業者開發非侵入性、實時監測和診斷測試。它提供唾液葡萄糖生物傳感器,這是一種用於糖尿病治療的有機薄膜晶體管,可以測量唾液中的葡萄糖。該公司還專注於開發SARS-CoV-2生物傳感器,生物傳感器測試可作為(RNA)病毒檢測測試的補充;以及一個由生物化學、免疫學、腫瘤標誌物、激素和核酸診斷模式組成的生物傳感器平臺。該公司前身為GBS Inc.,並於2022年10月更名為Intelligence Bio Solutions Inc.。該公司成立於2016年,總部設在紐約。智能生物解決方案公司是生命科學生物傳感器診斷有限公司的子公司。

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

接受Insulet Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Insulet和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論